HomeInvestors & MediaNews
ABL Bio To Present Phase 1 Data for ABL503 at ASCO 2024
- Poster to outline interim Phase 1 results for ABL503 (ragistomig) monotherapy in patients with advanced solid tumors- ABL503 is a bispecific antibody that combines two immune-oncology targets, PD-L1 and 4-1BB, based on ABL Bio’s proprietary Grabody-T platform technology- Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) in poster session scheduled for June 1, 2024 at 9:00 am CDT ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it will present a poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) regarding the interim results of the phase 1 clinical trial of ABL503 (TJ-L14B, ragistomig), an immunotherapy drug candidate which is being jointly developed with our global partner, I-Mab Biopharma. This is the first disclosure of ABL503 clinical data at a global scientific conference and this data will be presented at ASCO’s Developmental Therapeutics Immunotherapy poster session. ASCO is one of the world's top three cancer societies, and every year, many medical specialists, scientists, multinational pharmaceutical companies, and biotech companies attend and share the latest research results and anticancer drug’s clinical data. It will be held in Chicago from May 31st to June 4th. At this event, ABL Bio will present key data on the Dose Escalation and Dose Expansion portions of the ABL503 study in a poster. The title of the poster is ‘Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors’ and will be released for three hours from 9 a.m. to noon on June 1. ABL503 is a bispecific antibody that simultaneously targets PD-L1 and 4-1BB, which is involved in immune T cell activation. It was developed to overcome the limited response rate and resistance of existing PD-(L)1 treatments, and limit potential 4-1BB off target toxicity. Currently, the phase 1 clinical trial for patients with solid tumors is underway in the United States and Korea. The dose escalation part of the study, which sequentially increases the administered dose, is ongoing in the United States, and the dose expansion part of the study, to assess preliminary antitumor activity of a specific dose for which safety has been confirmed, as well as the tumor expansion part, which is carried out for selected specific cancer types, is ongoing in the United States and Korea. Sang Hoon Lee, CEO of ABL Bio, said, “ABL Bio is excited to share new, promising interim monotherapy results from new data from patients in the Phase 1 program for ragistomig at ASCO 2024, one of the world’s pre-eminent medical meetings. Ragistomig incorporates two powerful targets, PD-L1 and 4-1BB, into our proprietary Grabody-T bispecific antibody technology, ASCO is the second time that data from a product candidate using the 4-1BB bispecific antibody platform, Grabody-T will be presented.” and also stated, “We look forward to sharing the positive results achieved by ABL503 in the phase 1 clinical trial at ASCO.” Meanwhile, ABL Bio is developing various clinical and non-clinical assets based on the bispecific antibody platform ‘Grabody’. More than 15 clinical projects for more than 7 assets, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. In the case of ABL001, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to support the rapid development of new drugs. Assets such as ABL104 are also preparing to enter clinical trials. In addition, ABL Bio is continuously researching and developing several other non-clinical pipeline drugs, including bispecific ADCs.
2024-05-24ablbio
CStone Announces Presentation of Latest First-in-Human Data for CS5001 (ROR1 ADC) at ASCO 20...
https://www.cstonepharma.com/en/html/news/3693.html https://www.cstonepharma.com/en/html/news/3704.html
2024-05-24ablbio
SITC 2023 successfully ended with ABL Bio and I-Mab introducing ABL503/TJ-L14B and ABL111/TJ...
- ABL503 and ABL111, more powerful anti-cancer effect confirmed when administered in combination- ABL111 will be entered in clinical trial for triple combination therapy as a first-line treatment for gastroesophageal adenocarcinoma ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced that both the Company and its partner I-Mab (NASDAQ: IMAB) have successfully completed its poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) held from November 1 to 5 amid great interest in ABL503 (TJ-L14B) and ABL111 (TJ-CD4B, Givastomig). ABL503 and ABL111 are bispecific antibodies being jointly developed by ABL Bio and Nasdaq-listed company, I-Mab. ABL503 is undergoing phase 1 clinical trials in the United States and Korea, and ABL111 is undergoing phase 1 clinical trials in the United States and China. ABL503 is a bispecific antibody targeting PD-L1 and 4-1BB, and is developed to improve resistance and low response rates, which are considered as limitations of existing PD-(L)1 treatments. According to the ABL503 poster presented by ABL Bio at SITC, the combination therapy of ABL503 and PD-1 treatment appears to have a stronger anticancer effect by enhancing the activation of CD8+ T cells, which are immune cells in the tumor microenvironment. ABL Bio will flesh out its clinical plans for ABL503 combination therapy based on these non-clinical data. ABL111, another bispecific antibody introduced at SITC, simultaneously targets 4-1BB and Claudin18.2 which are overexpressed in gastric cancer, gastroesophageal junction cancer, and esophageal cancer. According to the ABL111 poster presented by I-Mab, T cells activated by ABL111 caused the death of not only Claudin18.2 positive tumor cells but also Claudin18.2 negative tumor cells. In addition, when ABL111 was administrated in combination with chemotherapy and PD-1 treatment, an increase in tumor-infiltrating lymphocytes and enhanced tumor killing effects were confirmed. Based on this, in order to obtain approval for ABL111 as a first-line treatment for gastroesophageal adenocarcinoma, follow-up clinical trials will be conducted on triple combination therapy that simultaneously administers ABL111, chemotherapy, and PD-1 treatment. Sang Hoon Lee, CEO of ABL Bio said “as presented at the SITC, the anticancer effects were found to be stronger when ABL503 administered in combination with immunotherapy, and when ABL111 administered in combination with chemotherapy and immunotherapy. ABL Bio and I-Mab plan to expand clinical trials of ABL503 and ABL111 based on these encouraging results.” And he also said “we will do our best to deliver good news from clinical trials.” Meanwhile, ABL Bio is developing more than 7 pipelines, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, and is conducting more than 14 clinical projects with different indications in various countries, including the United States, China, Australia, and Korea. Pipelines such as ABL104 are also preparing to enter clinical trials, and in addition, we are continuing to research and develop several non-clinical pipelines, including ABL102.
2023-11-07ablbio
ABL Bio presents posters about non-clinical data for ABL503 and ABL111 at SITC
- Non-clinical data on the anti-cancer effect of ABL503 and PD-1 treatment combination therapy will be presented- Partner company I-Mab introduces non-clinical data related to triple combination therapy of ABL111, chemotherapy, and PD-1 treatment ABL Bio (CEO Sanghoon Lee), a company specializing in bispecific antibody, announced that it will present the posters of ABL503 (TJ-L14B) and ABL111 (TJ-CD4B, Givastomig) at the 2023 Society for Immunotherapy of Cancer (SITC), which will be held from November 1 to 5. The poster of ABL503 is presented by ABL Bio, and the poster of ABL111 is introduced by its global partner I-Mab. I-Mab is a bio company listed on Nasdaq, USA. ABL Bio and I-Mab are jointly developing immuno-anticancer bispecific antibodies ABL503 and ABL111. ABL503 simultaneously targets PD-L1 and 4-1BB. It is developed to improve resistance and low response rates, which are limitations of existing PD-(L)1 treatments, and phase 1 clinical trials of ABL503 are currently underway in the United States and Korea. Although ABL503 is still in the early stages of clinical trials, one case of complete response (CR) and three cases of partial response (PR) have been confirmed in solid cancer patients. At this SITC, ABL Bio will present the results of non-clinical trials on the anticancer effect of ABL503 and PD-1 treatment combination therapy. ABL111 is a bispecific antibody that simultaneously targets 4-1BB and Claudin18.2 which is expressed in gastric cancer and gastroesophageal junction cancer, and attracted attention in October this year when I-Mab presented the interim results of phase 1 clinical trial that demonstrated excellent efficacy and safety at ESMO. At SITC, the strong anti-cancer effect of the triple combination therapy of ABL111, chemotherapy, and PD-1 treatment confirmed in non-clinical experiments will be introduced. Sang Hoon Lee, CEO of ABL Bio, said, “we are happy to present two posters at SITC, which has the highest authority in the field of immuno-oncology.” and he also said “recently, a combination of chemotherapy and PD-(L)1 treatment has been proposed as a standard treatment for cancer. We plan to develop ABL503 and ABL111 in line with this trend.” Meanwhile, ABL Bio is conducting global clinical trials for more than seven pipelines developed by the company, including ABL001, ABL111, ABL503, ABL105, ABL202, ABL301, and ABL103, in more than 14 countries, including the United States, China, Australia, and Korea. Pipelines such as ABL104 are also preparing to enter clinical trials, and in addition, ABL Bio is continuing to research and develop several non-clinical pipelines, including ABL102.
2023-10-31ablbio
ABL Bio, completed patent registration for ABL503 in Eurasia…smoothly securing global righ...
- Confirmed several CRㆍPR in global phase 1 clinical trial... value of oncology pipelines got highlighted- Guarantee of right in Eurasia for ‘ABL503 and its use’ by 2039 ABL Bio (CEO Sanghoon Lee), company specializing in BsAb (Bispecific Antibody), announced that it has completed patent (name of patent: anti-PD-L1/anti-4-1BB bispecific antibody and its use) registration for the immuno-oncology ABL503 in Eurasia that is consist of 8 countries including the Russian Federation on date. The patent right will be guaranteed until 2039. This patent has been registered in Chile, South Africa, Japan and Eurasia, and patent examination is in progress in more than 20 countries, including the United States, China and Europe. ABL503, which targets PD-L1 and 4-1BB at the same time, is drawing attention from industry by the news it confirmed 1 Complete Response(CR) case and 3 Partial Response(PR) cases for solid cancer patients even though it is still in phase 1 that is regarded as early stage. Especially, since CR, which means absence of all detectable cancer, rarely can be found in solid cancer, it is in limelight in that it can be used not only for monotherapy with strong anti-cancer effect but also has high potential as combination therapy with existing immunotherapies. Verifying superiority of its technology, ABL Bio is ensuring patent rights smoothly to enter global market. Led by Genmab that already has 7 approved antibody drugs so far, many global bio companies are developing PD-L1x4-1BB BsAb. However, ABL503 secured competitiveness by applying ABL Bio’s Grabody-T technology which makes it possible to have optimal epitope binding for 4-1BB activation. In particular, as ABL503 shows a favorable safety profile even at several times higher dose than 100 mg (flat dose) which is the effective dose in phase 1/2 of Genmab, it is regarded not only to be advantageous in defining RP2D(recommended phase 2 dose) but also to have superior efficacy from phase 2. ABL503 was developed to have superior efficacy and safety by targeting PD-L1 and 4-1BB at the same time to overcome the limitation of existing PD-(L)1 mechanism based immuno-therapy that shows effect only for 20% of total patients such as blockbuster immunotherapy Keytruda. In addition, while maintaining the advantage of treating various cancers, it minimizes toxicity and has anti-cancer effects to prevent long-term recurrence. Meanwhile, phase 1 of ABL503, which is being jointly developed with NASDAQ listed company I-Mab, is in dose escalation and dose expansion parts in the United States and Korea, and plans to secure safety data in monotherapy and determine RP2D & optimal tumor target. "It is encouraging that the amazing results of ABL503 have been confirmed from the phase 1 clinical trial. Prompt patent registration will make it easier to enter global market.” said Sanghoon Lee, CEO of ABL Bio. "Starting with the announcement of interim clinical phase 1 data of ABL111, 4-1BB-based BsAb immunotherapy, at the ESMO(European Society for Medical Oncology) in October this year, the value of immunotherapy pipelines will be recognized and highlighted," he said. Meanwhile, 7 pipeline including ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R), ABL103(H7-H4x4-1BB) that ABL Bio originally developed, are conducting over 14 clinical trials globally in the U.S., China, Australia, and South Korea. Furthermore, ABL104(EGFRx4-1BB) is planning to enter the phase 1 clinical trial. In addition, research and development of a number of non-clinical pipeline such as ABL102(ROR1x4-1BB), ABL602(CLL1xCD3) are also actively underway.
2023-10-10ablbio
ABL Bio, Confirms multiple complete and partial responses in phase 1 clinical trial of ABL50...
- Confirmed case of ‘complete response’ in solid tumor- The value of multiple Immuno-oncology pipeline will be highlighted ABL Bio(CEO Sanghoon Lee), a company specializing in bispecific antibodies, announced one case of complete response(CR) and three cases of partial response(PR) of ABL503(PD-L1 x 4-1BB) that is currently conducting a phase 1 clinical trial for solid tumor patients with NASDAQ-listed biotech, I-Mab. The CR case was confirmed in ovarian cancer, and the PR cases were confirmed in melanoma, gastric cancer and head and neck cancer. The phase 1 clinical trial of ABL503 is currently undergoing dose escalation and dose expansion at 6 sites and 3 sites in the U.S. and in South Korea respectively. ABL Bio plan to determine the RP2D(recommended phase 2 dose) and optimal target cancer. These cases, which are being confirmed at a clinical stage that is still only in the early stages, are attracting attention as they not only have a strong anti-cancer effect as a monotherapy, but also open up the possibility of use as a combination therapy with existing immunotherapy. Although the oncology market is one where numerous companies, including global pharmaceutical companies, are fiercely competing, it is expected that its commercial value, including the possibility of licensing-out and late-stage clinical trials of combination therapy, will be recognized as ABL Bio obtained such the clinical results. ABL503 is a bispecific antibody that combines the capabilities of PD-L1 checkpoint pathway inhibitor with 4-1BB agonistic activity to have advantage of being able to treat various tumor indications as the blockbuster immunotherapy, ‘Keytruda’. In addition, the Grabody-T platform is applied to activate 4-1BB only in immune cells surrounding tumor cells that express PD-L1, minimizing the toxic side effects of 4-1BB and preventing long-term recurrence. Furthermore, it is expected that ABL503 will be able to overcome the limited short-term efficacy and toxic side effects, which are pointed out as limitation in CD3 based bispecific antibodies and ADCs that have recently been highlighted. It is expected that ABL503 will hold a dominant position in global competition with 'GEN1046 (Genmab, Phase 2 clinical trial)' and 'INBRX-105 (Inibrix, Phase 1 clinical trial) in the development of PD-L1x4-1BB bispecific antibodies. In the case of GEN1046, the administered dose was already limited to 100mg (flat dose) in the phase 1/2 clinical dose expansion part, but in the case of ABL503, toxicity was not shown even when administered several times more than 100mg (flat dose). In other words, not only has superior safety already been secured compared to GEN1046, but it is also expected to be advantageous in determining the optimal administration dose (RP2D) for higher efficacy. Through this, it is expected that even more excellent efficacy will be shown from phase 2 clinical trials when the optimal dose is determined. In addition, ABL Bio will present clinical results of pipelines applying the 4-1BB-based Grabody-T platform one by one starting this year, positioning it the best-in-class among the global 4-1BB-based bispecific antibodies. It is expected that the immune-oncology pipeline being developed by ABL Bio will be re-evaluated through those the results of clinical trials. Meanwhile, the interim results of the phase 1 clinical trial of ABL111 will be announced at the European Society of Medical Oncology (ESMO 2023), which will be held from October 20 (Spanish local time) this year, and the interim results of the phase 1 clinical trial of ABL503 will be announced early next year. The plan is to maximize not only the value of pipeline, but also corporate value by continuing to accumulate these clinical results and reviewing various methods and measures, including licensing-out to global pharmaceutical companies. Dr. Sanghoon Lee, CEO of ABL Bio, said, “Many people tend to only focus on ABL Bio’s Neurodegenerative diseases treatment pipeline such as ABL301 and Grabody-B, but we are also committed to developing a variety of oncology pipeline. “As competition is fierce in the oncology market, more time was needed to obtain clinical results, and the interim clinical results of the 4-1BB-based pipeline have now begun to be disclosed. “ABL Bio’s pipeline have clear differences from existing treatments, so their value will also be highlighted,” he said, drawing attention to ABL Bio’s next moves to stand out in the oncology market, including the newly introduced bispecific antibody ADC. Meanwhile, 7 pipeline including ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R), ABL103(H7-H4x4-1BB) that ABL Bio originally developed, are conducting over 14 clinical trials globally in the U.S., China, Australia, and South Korea. Furthermore, ABL104(EGFRx4-1BB) is planning to enter the phase 1 clinical trial. In addition, research and development of a number of non-clinical pipeline such as ABL102(ROR1x4-1BB), ABL602(CLL1xCD3) are also actively underway.
2023-09-04ablbio
ABL Bio, Completed patent registration for ABL503 in Japan following Chile and South Africa
- Guarantee of right in Japan for ‘ABL503 and its use’ by 2039- Japan is regarded as major market in that cancer is the number one cause of death for Japanese. ABL Bio (CEO Sanghoon Lee) specializing in BsAb (Bispecific Antibody) company announced that it has completed patent (name of patent: anti-PD-L1/anti-4-1BB bispecific antibody and its use) registration in Japan for the immuno-oncology ABL503 on date. The patent in Japan was third registration after Chile and South Africa, and It is guaranteed its right until 2039. In addition, patent examination is in progress in more than 20 countries, including the United States, China and Europe. ABL503, which is under joint development with Nasdaq-listed company I-Mab, was developed to target PD-L1 and 4-1BB at the same time to overcome the limitation of prior PD-(L)1 mechanism based immuno-oncology that shows effect only for 20% of total patients. PD-L1x4-1BB is the one of BsAb models that is raising expectations because many global bio companies are conducting clinical trials for it including Genmab that already has 7 approved antibody drugs. In this competitive situation, ABL503 secured competitiveness by applying ABL Bio’s Grabody-T technology which makes it possible to have optimal epitope binding for 4-1BB activation. It has been verifying its superiority by showing great safety profile at higher dose than valid dose of other PD-L1x4-1BB BsAb pipelines in its ongoing clinical trial in US and South Korea. "Entering an super-aged society where the elderly population aged 65 or older accounts for nearly 30% of the total population, Japan’s national level of interest and support for national health are active, and especially cancer is the number one major cause of death for Japanese" said Sanghoon Lee CEO of ABL Bio. “As a PD-(L)1 mechanism based immuno-oncology that is effective in more than 20 indications, ABL503 is expect to have high competitiveness in the Japanese anticancer market in the future” he added. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-08-09ablbio
I-Mab, published manuscript of ABL111(TJ-CD4B) under co-development with ABL Bio on the inte...
- Demonstrated anti-tumor effect on CLDN18.2-expressing tumor through 4-1BB mediated T cell activation- Expected to be innovative treatment for gastric cancer patients that show a poor prognosis and have limited treatment options Nasdaq listed company I-Mab announced on date that it published manuscript of ABL111(TJ-CD4B, Givastomig) under co-development with ABL Bio on JITC(The journal for ImmunoTherapy of Cancer) which is official journal of SITC(Society for Immunotherapy of Cancer). Manuscript explains about anti-tumor effect of CLDN18.2x4-1BB BsAb Givastomig(hereafter ABL111) that is induced by activating T cell specifically at tumor expressing CLDN18.2, and original title is “Claudin18.2 and 4-1BB bispecific antibody Givastomig exerts anti-tumor activity through CLDN18.2-expressing tumor-directed T cell activation”. ABL111 which targets and binds to CLDN18.2 and 4-1BB at the same time induces potent tumor-killing effect by activating T cell specifically within CLDN18.2-expressing tumor. It is assessed as innovative approach to improve treatment effect in immunotherapy of gastric cancer which shows a poor prognosis and has limitation for treatment options. According to the results of the study, ABL111 binds to CLDN18.2 from low to high expression level and indicated the targeted effect by inducing 4-1BB activation only when it binds to CLDN18.2. Also, in in vivo model, ABL111 showed superior anti-tumor activity and long-lasting inhibition against tumor rechallenge by increasing CD8/Treg cell rate within tumors through immune activation. “The findings from our research demonstrate the significant potential of givastomig in treating gastric cancer patients with varying levels of CLDN18.2 expression,” said Dr. Lin Shen, Professor of Clinical Oncology at the Beijing Cancer Hospital of Peking University, Director of SIP LifeLink Oncology Research Institute, and principal investigator of the first-in-human study of givastomig (NCT04900818). “By activating 4-1BB signaling in a CLDN18.2 engagement-dependent manner, givastomig can avoid the risk of liver toxicity and systemic immune response commonly observed with other 4-1BB stimulating agents in previous clinical trials.” “We are excited to see this manuscript published in JITC, as it showcases the innovative design and remarkable anti-tumor activity in preclinical models of givastomig,” said Dr. Andrew Zhu, President of I-Mab. “This bispecific antibody has demonstrated promising results in preclinical models and ongoing clinical study by effectively activating T cells and triggering a localized immune response within the tumor microenvironment. With ongoing clinical studies, we aim to build upon these findings and ultimately make this innovative therapy accessible to patients with gastric cancer.” “It is glad that immuno-oncology pipeline ABL111’s great efficacy got recognized and introduced through international journal” said Sanghoon Lee, CEO of ABL Bio. “We will keep our active academic activity with ongoing clinical trials including ABL503’s Korea phase 1 expansion and ABL103’s Korea phase 1 that both were began in 2023” he added. ABL111’s clinical trial phase 1 is in progress smoothly in US and China, and it is encouraging that it has shown favorable safety profile and promising efficacy so far in phase 1. Clinical data will be disclosed at major medical conferences by I-Mab within the second half. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-07-06ablbio
ABL Bio, Completed patent registration for ABL503 in Chile & South Africa
- Guarantee of rights in each country for ABL503 and its use by 2039- Multinational patent acquisition adds flexibility to clinical and commercialization strategies ABL Bio (CEO Sanghoon Lee) specializing in BsAb (Bispecific Antibody) company announced that it has completed patent (name of patent: anti-PD-L1/anti-4-1BB bispecific antibody and its use) registration in Chile and South Africa for the immuno-oncology ABL503 on date. These patents are guaranteed their rights until 2039. In addition, patent examination is in progress in more than 20 countries, including the United States, China, Europe, and Japan. ABL503, which is under joint development with Nasdaq-listed company I-Mab, is a BsAb pipeline that targets PD-L1 and 4-1BB at the same time. In the case of PD-(L)1 mechanism-based blockbuster drug Keytruda, it is widely applicable to more than 20 kinds of cancer, but there is still a limitation that it is effective for only 20% of total patients. ABL503, developed to overcome the limitation of these PD-(L)1 mechanism-based immuno-oncology, is a BsAb that combines PD-L1 target antibody with 4-1BB target antibody, and is designed to show improved efficacy by enhancing immune cell activity and adding memory T-cell activation. ABL503’s phase 1 clinical trial is progressing smoothly in the United States and South Korea, also it is expected to have differentiated strength in searching optimal dose with great safety profile at higher dose than valid dose of other companies’ PD-L1x4-1BB BsAb phase 2. "In the case of pure R&D-based biotech company like ABL Bio, the protection of intellectual property rights including patents, is as important as R&D of new drugs," said Sanghoon Lee CEO of ABL Bio. “Patent registration in various countries will also create more opportunities and flexibility in establishing clinical and commercialization strategies for new drug pipelines in the future” he explained the meaning of patent registration. Meanwhile, ABL Bio's more than 6 pipelines such as ABL001(VEGFxDLL4), ABL111(Claudin18.2x4-1BB), ABL503(PD-L1x4-1BB), ABL105(HER2x4-1BB), ABL202(ROR1 ADC), ABL301(a-synxIGF1R) etc. are under global clinical trial by ABL Bio or by its partners in the US, China, Australia and Korea. Pipelines such as ABL103(B7-H4x4-1BB) and ABL104(EGFRx4-1BB) etc. are also under preparation to enter clinical trials by ABL Bio or by its partners. In addition, a number of non-clinical pipelines including ABL602(CLL1xCD3) are also actively underway.
2023-07-05ablbio